BATS:HELX Franklin Genomic Advancements ETF (HELX) Price, Holdings, & News $35.43 -0.20 (-0.56%) As of 05/29/2026 04:10 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartDividendHoldingsOwnershipRatingsShort InterestBuy This Stock About Franklin Genomic Advancements ETF (BATS:HELX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get HELX alerts:Sign Up Key Stats Today's Range$35.43▼$35.4350-Day Range$31.24▼$35.6352-Week Range$25.89▼$38.17Volume151 shsAverage Volume1,039 shsMarket Capitalization$14.17 millionAssets Under Management$23.02 millionDividend YieldN/ANet Expense Ratio0.50%Aggregate RatingModerate Buy ETF Overview The Franklin Genomic Advancements ETF (HELX) is an exchange-traded fund that is based on the Solactive Genomics index. The fund is an actively managed portfolio of global equity securities of companies relevant to genomic discovery. HELX was launched on Feb 25, 2020 and is managed by Franklin Templeton. Read More Franklin Genomic Advancements ETF ExpensesTypeHELXTheme ETFsEquity ETFsBATS ETFsAll ETFsManagement Fee0.50%0.57%0.57%0.59%0.53%Other Expenses0.00%0.57%0.55%0.45%0.55%Total Expense0.50%0.73%0.76%0.72%0.73%Fee Waiver0.00%-0.75%-0.64%-0.40%-0.62%Net Expense0.50%0.60%0.63%0.65%0.60% Receive HELX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Franklin Genomic Advancements ETF and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. HELX ETF News HeadlinesFranklin Genomic Advancements ETF - Markets InsiderJuly 23, 2025 | markets.businessinsider.comFranklin Emerging Markets UCITS ETF (FLXE)September 18, 2024 | investing.comHow to claim a stake in SpaceX before the June 12 IPOSpaceX is expected to go public on June 12 - and for the first time, everyday investors may have a way in before the IPO. Jeff Brown, who identified Bitcoin, Tesla, and Nvidia before gains as high as 52,400%, 2,150%, and 32,000% respectively, is sharing the details on how to claim a stake in Elon Musk's company before it hits public markets.May 30 at 1:00 AM | Brownstone Research (Ad)Franklin Ethereum ETF (EZET)August 2, 2024 | finance.yahoo.comChainlink Integration Enhances Transparency for 21Shares’ Ether ETFJuly 30, 2024 | msn.comFranklin Catholic Princ Em Sov Ucits Etf Share Price (CATHEM.MI)April 23, 2024 | lse.co.ukSee More Headlines HELX ETF - Frequently Asked Questions How have HELX shares performed this year? Franklin Genomic Advancements ETF's stock was trading at $36.35 on January 1st, 2026. Since then, HELX stock has decreased by 2.5% and is now trading at $35.43. How do I buy shares of Franklin Genomic Advancements ETF? Shares of HELX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Franklin Genomic Advancements ETF own? Based on aggregate information from My MarketBeat watchlists, some other companies that Franklin Genomic Advancements ETF investors own include Merck & Co., Inc. (MRK), iShares iBonds Dec 2025 Term Muni Bond ETF (IBMN), Novavax (NVAX) and AbbVie (ABBV). Fund Details IssuerFranklin Templeton Investments Fund NameFranklin Genomic Advancements ETF Tax ClassificationRegulated Investment Company Stock ExchangeBATSCurrent SymbolBATS:HELX Inception Date2/25/2020 Fund ManagerMatthew J.Moberg, Joyce Lin WebN/A PhoneN/AFund Focus Asset ClassEquity BenchmarkN/A CategoryStrategy FocusTheme Development LevelBlended Development RegionGlobal Number of Holdings64 Fund Statistics Assets Under Management$23.02 million Average Daily Volume$0.00 Discount/Premium0.02% Administrator, Advisor and Custodian AdministratorFranklin Templeton Services, LLC AdvisorFranklin Advisers, Inc. CustodianThe Bank of New York Mellon Corporation DistributorFranklin Templeton Distributors, Inc. Transfer AgentThe Bank of New York Mellon Corporation TrusteeN/A Lead Market MakerCitadel Options OptionableOptionable Options Volume1 Put Options1 Call Options1 Miscellaneous Outstanding Shares400,000Beta1.05 Creation Unit50,000 Creation Fee$200.00 The Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free Report Top 10 HELX HoldingsGuardant Health (NASDAQ:GH)Holding Weight: 7.12%Natera (NASDAQ:NTRA)Holding Weight: 6.50%Krystal Biotech (NASDAQ:KRYS)Holding Weight: 6.10%United Therapeutics (NASDAQ:UTHR)Holding Weight: 4.51%BridgeBio Pharma (NASDAQ:BBIO)Holding Weight: 3.77%Ligand Pharmaceuticals (NASDAQ:LGND)Holding Weight: 3.73%AstraZeneca PLCHolding Weight: 3.22%Insmed (NASDAQ:INSM)Holding Weight: 3.01%Vertex Pharmaceuticals (NASDAQ:VRTX)Holding Weight: 2.96%Adaptive Biotechnologies (NASDAQ:ADPT)Holding Weight: 2.90%Full Holdings DetailsHELX Sector ExposureHELX Industry Exposure This page (BATS:HELX) was last updated on 5/30/2026 by MarketBeat.com Staff. From Our PartnersCODE RED: AI Meltdown Imminent?After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...Paradigm Press | SponsoredYour book attachedYour Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...Profits Run | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredSkip the Line Opportunity: The SpaceX IPOFormer tech executive and angel investor Jeff Brown - who identified Bitcoin, Tesla, and Nvidia before their h...Brownstone Research | SponsoredHey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...Banyan Hill Publishing | SponsoredTrump just signed itA recent policy development is drawing attention from income-focused investors. According to one analyst, c...Investors Alley | SponsoredPH: Do THESE 4 things to your bank account now …In a few short months, the US government could gain unprecedented powers over personal bank accounts - includi...Weiss Ratings | SponsoredHow to buy into SpaceX before the IPO for under 100 dollarsSpaceX is targeting an IPO on June 11th, with trading set to begin June 12th and the roadshow kicking off June...NXT Wave Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Franklin Genomic Advancements ETF Please log in to your account or sign up in order to add this asset to your watchlist. Share Franklin Genomic Advancements ETF With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
